PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för olomoucine. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

10 hits

Bibliografisk träff 2016-06-21

Down-regulation of BNIP3 by olomoucine, a CDK inhibitor, reduces LPS- and NO-induced cell death in BV2 microglial cells.

Tsou YC, Wang HH, Hsieh CC, Sun KH, Sun GH, Jhou RS, Lin TI, Lu SY, Liu HY, Tang SJ.

Neurosci Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.neulet.2016.06.040

Bibliografisk träff 2016-05-27

The effect of cyclin-dependent kinases inhibitor treatment on experimental herpes simplex encephalitis mice.

Zhou Y, Zeng YP, Zhou Q, Guan JX, Lu ZN.

Neurosci Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.neulet.2016.05.059

Bibliografisk träff 2014-10-01

Synergistic actions of olomoucine and bone morphogenetic protein-4 in axonal repair after acute spinal cord contusion.

Chen L, Li J, Wu L, Yang M, Gao F, Yuan L.

Neural Regen Res · other; journal article · DOI 10.4103/1673-5374.143431

Bibliografisk träff 2009-08-01

Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells?

Wandl S, Wesierska-Gadek J.

Ann N Y Acad Sci · research support, non-u.s. gov't; journal article · DOI 10.1111/j.1749-6632.2009.04700.x

Bibliografisk träff 2008-03-17

The Cdk5 inhibitor olomoucine promotes corneal debridement wound closure in vivo.

Tripathi BK, Stepp MA, Gao CY, Zelenka PS.

Mol Vis · research support, n.i.h., intramural; research-article; journal article; research support, n.i.h., extramural

Bibliografisk träff 2006-09-01

Cyclin-dependent kinase (CDK) inhibitor olomoucine enhances gamma-irradiation-induced apoptosis and cell cycle arrest in Raji cells.

Boutis A, Papazisis K, Pistevou-Gompaki K, Lambropoulos A, Sofroniadis I, Papageorgiou A, Destouni E, Kortsaris A.

Anticancer Res · journal article

Bibliografisk träff 2002-08-01

Synthetic inhibitors of CDKs induce different responses in androgen sensitive and androgen insensitive prostatic cancer cell lines.

Mad'arová J, Lukesová M, Hlobilková A, Strnad M, Vojtesek B, Lenobel R, Hajdúch M, Murray PG, Perera S, Kolár Z.

Mol Pathol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1136/mp.55.4.227

Bibliografisk träff 1995-01-01

Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases.

Abraham RT, Acquarone M, Andersen A, Asensi A, Bellé R, Berger F, Bergounioux C, Brunn G, Buquet-Fagot C, Fagot D.

Biol Cell · research support, non-u.s. gov't; journal article · DOI 10.1016/0248-4900(96)81298-6

Bibliografisk träff 1994-10-01

Olomoucine, an inhibitor of the cdc2/cdk2 kinases activity, blocks plant cells at the G1 to S and G2 to M cell cycle transitions.

Glab N, Labidi B, Qin LX, Trehin C, Bergounioux C, Meijer L.

FEBS Lett · journal article · DOI 10.1016/0014-5793(94)01035-8

Bibliografisk träff 1994-09-01

Inhibition of cyclin-dependent kinases by purine analogues.

Veselý J, Havlicek L, Strnad M, Blow JJ, Donella-Deana A, Pinna L, Letham DS, Kato J, Detivaud L, Leclerc S.

Eur J Biochem · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1111/j.1432-1033.1994.00771.x